Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $310
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Amgen (NASDAQ:AMGN) and increased the price target from $271 to $310.

May 03, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Amgen, raising the price target to $310.
The increase in price target by Morgan Stanley suggests a positive outlook on Amgen's stock value in the short term. This adjustment reflects an expectation of stronger performance or favorable market conditions for Amgen, likely leading to increased investor interest and potentially a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100